The global microbial therapeutic products market size was worth USD 63,281.50 million in 2021 and is estimated to grow to about USD 95,502.24 million by 2028, with a compound annual growth rate (CAGR) of around 7.10 percent during the forecast period.
The global microbial therapeutic products market size was worth USD 63,281.50 million in 2021 and is estimated to grow to USD 95,502.24 million by 2028, with a compound annual growth rate (CAGR) of approximately 7.10 percent over the forecast period. The report analyzes the microbial therapeutic products market's drivers, restraints/challenges, and their effect on the demands during the projection period. In addition, the report explores emerging opportunities in the microbial therapeutic products market.
Microorganisms form microbial products, and the microbial manufacturing biotechnology industry is related to this area. These bacteria have been used for decades to make cheese, bread, vinegar, and wine, among many others. Medical microbiology includes enzymes, antibiotics, nutrients such as amino acids, vitamins, and organic acids, as well as vaccine production. The growing demand for healthcare nutrients such as vitamins, coupled with the increasing demand for diagnostic microbiology products, is expected to drive the market in the forecast years. At the same time, budget constraints of small and medium-sized market players hamper the market growth during the forecast period.
The COVID-19 pandemic has impacted the businesses of microbial therapeutic. The COVID-19 pandemic spread throughout the world as strict lock-downs are implemented by governments and shut down companies. Thus, the movement of people is restricted during the covid-19 pandemic; the global microbial therapeutic products market is likely to be impacted considerably during the forecast period. Besides that, the uncertain use of these microbial therapeutic products affected the market growth during the pandemic period.
The growing demand for healthcare nutrients aids the global market growth
According to analysts, the growing demand for healthcare nutrients such as vitamins and the increasing demand for diagnostic microbiology products is expected to drive the market in the forecast years. In addition, the rise of diseases such as cancer is expected to boost the industry in the coming years. Other factors expected to drive the global microbial therapeutic products market growth during the estimated period include enzyme production for end-use industries such as food preservation, leather, and paper. Several limitations and issues need to be overcome for the market to continue to grow.
The lack of accuracy may hamper the global market growth
The key restraints for the global microbial therapeutic products market are the lack of accurate information. Some aspects of specific microscopic organisms can be transferred to non-critical species, which poses a challenge in determining drug efficacy.
The adoption of technology brings up several growth opportunities
Fermentation technology is the most widely applied method for producing microbial products that convert sugars into gases, alcohols, or acids. Increasing advances in fermentation technology can change the entire production process of microbial products. Usually, fermentation depends on using limited raw materials, and different bacterial strains have meager yields. But new recombinant technology is being used to manipulate the structure of microorganisms to increase their efficiency and make them capable of using various raw materials. Furthermore, by using these engineered microorganisms, the production of microbial products can be achieved more naturally and economically by introducing mutations into the organism. Pl plasmids and vectors for gene amplification are one of the modern advances in biotechnology to increase bacteria's productivity.
The global microbial therapeutic products market is segregated based on product, route of administration, source, application, end-user, and region.
By source, the market is divided into bacteria and fungi. Among these, the microbial therapies derived from bacteria are expected to remain profitable as they are widely available from various sources. In addition, microorganisms perform the function of setting events and producing medicinal drugs, including anti-infective agents and nutrients. Given their harmless nature, the stomach microbiome has been a well-known source of refined bacteria over time. Gut bacteria are very beneficial in treating digestive problems and food poisoning.
By application, the market is bifurcated into metabolic disorders, hematological disorders, oncology, immunological disorders, infectious diseases, allergic diseases, and others. Over the forecast period, oncology and metabolic disorders are expected to account for a significant share of the global market. As indicated by research, Bacteriocin’s anti-infectives, chemicals, and peptides have great potential to provide drugs against malignant growth. Oncology seems to be the most promising candidate for future drug development.
Report Attribute | Details |
---|---|
Base Year | 2020 |
Historic Years | 2016 - 2020 |
Forecast Years | 2021 - 2028 |
Segments Covered | By Product Type, By Application, and By End Use |
Forecast Units | Value (USD Billion), and Volume (Units) |
Quantitative Units | Revenue in USD million/billion and CAGR from 2021 to 2028 |
Regions Covered | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World |
Countries Covered | U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others |
Number of Companies Covered | 10 companies with scope for including additional 15 companies upon request |
Report Coverage | Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis. |
Customization Scope | Avail customized purchase options to meet your exact research needs. |
The presence of market players and advancements help North America dominate the global market
North America is expected to be the dominant region in the global microbial therapeutic products market during the forecast period due to technological advances and increased industry research and development investment. Each year, the personal care industry in the United States reaches an increasingly high level of development. Women nationwide use 12 unique care products daily, while men use an average of six products daily. With more independent companies with shorter supply chains and greater resonance with younger customers, consumer spending has shifted primarily to skin care. Cosmetics are an essential component of the personal care business in the country, and some larger companies are having trouble complying with the definition of probiotics as living organisms in molded microbiological products.
Some of the main competitors dominating the global microbial therapeutic products market include - Amgen Inc., F. Hoffmann La-Roche Ltd., Mylan N.V., Novartis AG, Biocon, Merck & Co. Inc., Pfizer Inc., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Sanofi S.A., Boehringer Ingelheim, Bristol-Myers Squibb Company, Novo Nordisk A/S, and Abbot Laboratories.
By Product
By Route of Administration
By Source
By Application
By End-user
By Region
According to analysts, the growing demand for healthcare nutrients such as vitamins, coupled with the increasing demand for diagnostic microbiology products, is expected to drive the market in the forecast years. In addition, the rise of diseases such as cancer is expected to boost the industry in the coming years. Other factors expected to drive market growth during the estimated period include enzyme production for end-use industries such as food preservation, leather, and paper. Several limitations and issues need to be overcome for the market to continue to grow.
According to a report, the global microbial therapeutic products market size was worth 63,281.50 (USD million) in 2021 and is predicted to grow to 95,502.24 (USD Million) by 2028 with a compound annual growth rate (CAGR) of about 7.10 percent.
North America is expected to be the dominant market during the forecast period due to technological advances and increased industry research and development investment. Each year, the personal care industry in the United States reaches an increasingly high level of development.
Some of the main competitors dominating the global microbial therapeutic products market include Amgen Inc., F. Hoffmann La-Roche Ltd., Mylan N.V., Novartis AG, Biocon, Merck & Co. Inc., Pfizer Inc., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Sanofi S.A., Boehringer Ingelheim, Bristol-Myers Squibb Company, Novo Nordisk A/S, and Abbot Laboratories.
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed